Phase 3 prospective multicenter open label study to investigate safety immnogenicity and hemostatic efficacy of PEGylated Factor VIII(BAX 855) in previously untreated patients(PUPs)6 years with severe Hemophilia A (FVIII1)(Protocol Number 261203)